The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Benign Prostatic Hyperplasia Testing-Global Market Insights and Sales Trends 2024
Synopsis
Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of the prostate doubles and the second growth phase starts at 25 years and continues throughout the lifetime. While the prostate gland enlarges in a man, it presses and pinches the urethra making the bladder wall thick. This pressure and squeeze on the urethra weaken the bladder and makes it lose the ability to empty the urine completely. Urinary retention and narrowing of the urethra can cause many problems which are associated with benign prostatic hyperplasia. Benign prostatic hyperplasia is one of the common prostate problems for men older than age 50.
The global Benign Prostatic Hyperplasia Testing market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Benign Prostatic Hyperplasia Testing in various end use industries. The expanding demands from the Hospitals, Diagnostic Centers, Clinics and Research Institutes, are propelling Benign Prostatic Hyperplasia Testing market. Urinalysis, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Prostate-Specific Antigen (PSA) Blood Test segment is estimated at % CAGR for the next seven-year period.
Benign prostatic hyperplasia testing market is primarily driven by a few key factors such as the growing geriatric male population, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure, increasing government initiatives and availability of minimally invasive surgery as a drug replacement, faster and easy performing diagnosis test results. The market is likely to grow owing to the novel diagnostic methods which are accurate than the conventional PSA blood test for benign prostatic hyperplasia which is effective in diagnosis and is expected to fuel the growth of benign prostatic hyperplasia testing market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Benign Prostatic Hyperplasia Testing, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Benign Prostatic Hyperplasia Testing market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Benign Prostatic Hyperplasia Testing market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Benign Prostatic Hyperplasia Testing sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Benign Prostatic Hyperplasia Testing covered in this report include AEternaZentaris, Astellas Pharma, Eli Lilly and Company, IntelGenx Technologies Corp, Nymox Pharmaceutical Corporation, Protox Therapeutics and Quest PharmaTech, etc.
The global Benign Prostatic Hyperplasia Testing market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
Global Benign Prostatic Hyperplasia Testing market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Benign Prostatic Hyperplasia Testing market, Segment by Type:
Urinalysis
Prostate-Specific Antigen (PSA) Blood Test
Urodynamic Test
Cystoscopy
Global Benign Prostatic Hyperplasia Testing market, by Application
Hospitals
Diagnostic Centers
Clinics
Research Institutes
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Benign Prostatic Hyperplasia Testing companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of the prostate doubles and the second growth phase starts at 25 years and continues throughout the lifetime. While the prostate gland enlarges in a man, it presses and pinches the urethra making the bladder wall thick. This pressure and squeeze on the urethra weaken the bladder and makes it lose the ability to empty the urine completely. Urinary retention and narrowing of the urethra can cause many problems which are associated with benign prostatic hyperplasia. Benign prostatic hyperplasia is one of the common prostate problems for men older than age 50.
The global Benign Prostatic Hyperplasia Testing market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Benign Prostatic Hyperplasia Testing in various end use industries. The expanding demands from the Hospitals, Diagnostic Centers, Clinics and Research Institutes, are propelling Benign Prostatic Hyperplasia Testing market. Urinalysis, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Prostate-Specific Antigen (PSA) Blood Test segment is estimated at % CAGR for the next seven-year period.
Benign prostatic hyperplasia testing market is primarily driven by a few key factors such as the growing geriatric male population, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure, increasing government initiatives and availability of minimally invasive surgery as a drug replacement, faster and easy performing diagnosis test results. The market is likely to grow owing to the novel diagnostic methods which are accurate than the conventional PSA blood test for benign prostatic hyperplasia which is effective in diagnosis and is expected to fuel the growth of benign prostatic hyperplasia testing market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Benign Prostatic Hyperplasia Testing, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Benign Prostatic Hyperplasia Testing market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Benign Prostatic Hyperplasia Testing market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Benign Prostatic Hyperplasia Testing sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Benign Prostatic Hyperplasia Testing covered in this report include AEternaZentaris, Astellas Pharma, Eli Lilly and Company, IntelGenx Technologies Corp, Nymox Pharmaceutical Corporation, Protox Therapeutics and Quest PharmaTech, etc.
The global Benign Prostatic Hyperplasia Testing market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
Global Benign Prostatic Hyperplasia Testing market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Benign Prostatic Hyperplasia Testing market, Segment by Type:
Urinalysis
Prostate-Specific Antigen (PSA) Blood Test
Urodynamic Test
Cystoscopy
Global Benign Prostatic Hyperplasia Testing market, by Application
Hospitals
Diagnostic Centers
Clinics
Research Institutes
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Benign Prostatic Hyperplasia Testing companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Benign Prostatic Hyperplasia Testing
1.1 Benign Prostatic Hyperplasia Testing Market Overview
1.1.1 Benign Prostatic Hyperplasia Testing Product Scope
1.1.2 Benign Prostatic Hyperplasia Testing Market Status and Outlook
1.2 Global Benign Prostatic Hyperplasia Testing Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Benign Prostatic Hyperplasia Testing Market Size by Region (2018-2029)
1.4 Global Benign Prostatic Hyperplasia Testing Historic Market Size by Region (2018-2023)
1.5 Global Benign Prostatic Hyperplasia Testing Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Benign Prostatic Hyperplasia Testing Market Size (2018-2029)
1.6.1 North America Benign Prostatic Hyperplasia Testing Market Size (2018-2029)
1.6.2 Europe Benign Prostatic Hyperplasia Testing Market Size (2018-2029)
1.6.3 Asia-Pacific Benign Prostatic Hyperplasia Testing Market Size (2018-2029)
1.6.4 Latin America Benign Prostatic Hyperplasia Testing Market Size (2018-2029)
1.6.5 Middle East & Africa Benign Prostatic Hyperplasia Testing Market Size (2018-2029)
2 Benign Prostatic Hyperplasia Testing Market by Type
2.1 Introduction
2.1.1 Urinalysis
2.1.2 Prostate-Specific Antigen (PSA) Blood Test
2.1.3 Urodynamic Test
2.1.4 Cystoscopy
2.2 Global Benign Prostatic Hyperplasia Testing Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Benign Prostatic Hyperplasia Testing Historic Market Size by Type (2018-2023)
2.2.2 Global Benign Prostatic Hyperplasia Testing Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Benign Prostatic Hyperplasia Testing Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Benign Prostatic Hyperplasia Testing Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Benign Prostatic Hyperplasia Testing Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Benign Prostatic Hyperplasia Testing Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Benign Prostatic Hyperplasia Testing Revenue Breakdown by Type (2018-2029)
3 Benign Prostatic Hyperplasia Testing Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Diagnostic Centers
3.1.3 Clinics
3.1.4 Research Institutes
3.2 Global Benign Prostatic Hyperplasia Testing Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Benign Prostatic Hyperplasia Testing Historic Market Size by Application (2018-2023)
3.2.2 Global Benign Prostatic Hyperplasia Testing Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Benign Prostatic Hyperplasia Testing Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Benign Prostatic Hyperplasia Testing Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Benign Prostatic Hyperplasia Testing Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Benign Prostatic Hyperplasia Testing Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Benign Prostatic Hyperplasia Testing Revenue Breakdown by Application (2018-2029)
4 Benign Prostatic Hyperplasia Testing Competition Analysis by Players
4.1 Global Benign Prostatic Hyperplasia Testing Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Testing as of 2022)
4.3 Date of Key Players Enter into Benign Prostatic Hyperplasia Testing Market
4.4 Global Top Players Benign Prostatic Hyperplasia Testing Headquarters and Area Served
4.5 Key Players Benign Prostatic Hyperplasia Testing Product Solution and Service
4.6 Competitive Status
4.6.1 Benign Prostatic Hyperplasia Testing Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AEternaZentaris
5.1.1 AEternaZentaris Profile
5.1.2 AEternaZentaris Main Business
5.1.3 AEternaZentaris Benign Prostatic Hyperplasia Testing Products, Services and Solutions
5.1.4 AEternaZentaris Benign Prostatic Hyperplasia Testing Revenue (US$ Million) & (2018-2023)
5.1.5 AEternaZentaris Recent Developments
5.2 Astellas Pharma
5.2.1 Astellas Pharma Profile
5.2.2 Astellas Pharma Main Business
5.2.3 Astellas Pharma Benign Prostatic Hyperplasia Testing Products, Services and Solutions
5.2.4 Astellas Pharma Benign Prostatic Hyperplasia Testing Revenue (US$ Million) & (2018-2023)
5.2.5 Astellas Pharma Recent Developments
5.3 Eli Lilly and Company
5.3.1 Eli Lilly and Company Profile
5.3.2 Eli Lilly and Company Main Business
5.3.3 Eli Lilly and Company Benign Prostatic Hyperplasia Testing Products, Services and Solutions
5.3.4 Eli Lilly and Company Benign Prostatic Hyperplasia Testing Revenue (US$ Million) & (2018-2023)
5.3.5 IntelGenx Technologies Corp Recent Developments
5.4 IntelGenx Technologies Corp
5.4.1 IntelGenx Technologies Corp Profile
5.4.2 IntelGenx Technologies Corp Main Business
5.4.3 IntelGenx Technologies Corp Benign Prostatic Hyperplasia Testing Products, Services and Solutions
5.4.4 IntelGenx Technologies Corp Benign Prostatic Hyperplasia Testing Revenue (US$ Million) & (2018-2023)
5.4.5 IntelGenx Technologies Corp Recent Developments
5.5 Nymox Pharmaceutical Corporation
5.5.1 Nymox Pharmaceutical Corporation Profile
5.5.2 Nymox Pharmaceutical Corporation Main Business
5.5.3 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Testing Products, Services and Solutions
5.5.4 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Testing Revenue (US$ Million) & (2018-2023)
5.5.5 Nymox Pharmaceutical Corporation Recent Developments
5.6 Protox Therapeutics
5.6.1 Protox Therapeutics Profile
5.6.2 Protox Therapeutics Main Business
5.6.3 Protox Therapeutics Benign Prostatic Hyperplasia Testing Products, Services and Solutions
5.6.4 Protox Therapeutics Benign Prostatic Hyperplasia Testing Revenue (US$ Million) & (2018-2023)
5.6.5 Protox Therapeutics Recent Developments
5.7 Quest PharmaTech
5.7.1 Quest PharmaTech Profile
5.7.2 Quest PharmaTech Main Business
5.7.3 Quest PharmaTech Benign Prostatic Hyperplasia Testing Products, Services and Solutions
5.7.4 Quest PharmaTech Benign Prostatic Hyperplasia Testing Revenue (US$ Million) & (2018-2023)
5.7.5 Quest PharmaTech Recent Developments
6 North America
6.1 North America Benign Prostatic Hyperplasia Testing Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Testing Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Testing Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Testing Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Testing Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Benign Prostatic Hyperplasia Testing Market Dynamics
11.1 Benign Prostatic Hyperplasia Testing Industry Trends
11.2 Benign Prostatic Hyperplasia Testing Market Drivers
11.3 Benign Prostatic Hyperplasia Testing Market Challenges
11.4 Benign Prostatic Hyperplasia Testing Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
